Two Massachusetts researchers have received federal grants to work on developing a process for manufacturing pharmaceutical-quality CBD, and to create a synthetic compound that will be medically beneficial without getting patients high, the article reports. It is believed that by harnessing CBD’s, such drugs will have the potential to treat conditions including:
- Psychiatric Disorders
- Chronic Pain
While there is a lot of interest into groundbreaking drugs containing CBD’s, marijuana is still illegal on the federal level, which makes it difficult to conduct studies on a national level. However, Aphios Corporation, a Massachusetts-based biotechnology company, has been granted access to the government’s research-grade marijuana to conduct studies. The company will work on developing CBD drugs for researchers to use for study purposes.
“There is a lot of interest from the medical marijuana marketplace, and that is pushing institutions to try and investigate why these things are working and how well are they working,” said Trevor Castor, Chief Executive at Aphios.